Area of research
Infectious Diseases · Clinical Psychology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, COVID-19 and Mental Health, and SARS-CoV-2 detection and testing.
SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency
Rapid spread of the SARS-CoV-2 JN.1 lineage is associated with increased neutralization evasion
Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5
Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination
Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage
Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3
Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccine
Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation
SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies
BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy
Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis
The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency
Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination
SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods
Perceived versus proven SARS-CoV-2-specific immune responses in health-care professionals
Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals